Adeno-associated viruses (AAV) are small viruses that infect humans and some other primate species. They belong to the genus Dependoparvovirus, which in turn belongs to the family Parvoviridae. They are small (20 nm) replication-defective, nonenveloped viruses and have linear single-stranded DNA (ssDNA) genome of approximately 4.8 kilobases (kb).

The global Adeno-Associated Virus Vectors in Gene Therapy market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.

The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

This report aims to provide a comprehensive presentation of the global market for Adeno-Associated Virus Vectors in Gene Therapy, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Adeno-Associated Virus Vectors in Gene Therapy.

Report Scope

The Adeno-Associated Virus Vectors in Gene Therapy market size, estimations, and forecasts are provided in terms of sales volume (Kg) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Adeno-Associated Virus Vectors in Gene Therapy market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Adeno-Associated Virus Vectors in Gene Therapy manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Market Segmentation

Scope of Adeno-Associated Virus Vectors in Gene Therapy Market Report

Report Metric	Details
Report Name	Adeno-Associated Virus Vectors in Gene Therapy Market
CAGR	5%
Segment by Type	Serotype 2 (AVV 2) Synthetic Serotypes Others
Segment by Application	Alzheimer's Disease Cystic Dibrosis Hemophilia B Parkinson's Disease
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Amicus Therapeutics, Asklepios Biopharmaceutical, BioMarin Pharmaceutical, Coave Therapeutics, MeiraGTx, Neurocrine Biosciences, Pfizer, Roche Holding, Sangamo Therapeutics, Sarepta Therapeutics, Spark Therapeutics, Voyager Therapeutics, NightstaRx
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Adeno-Associated Virus Vectors in Gene Therapy manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Adeno-Associated Virus Vectors in Gene Therapy in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

Who are the main players in the Adeno-Associated Virus Vectors in Gene Therapy Market report?

Ans: The main players in the Adeno-Associated Virus Vectors in Gene Therapy Market are Amicus Therapeutics, Asklepios Biopharmaceutical, BioMarin Pharmaceutical, Coave Therapeutics, MeiraGTx, Neurocrine Biosciences, Pfizer, Roche Holding, Sangamo Therapeutics, Sarepta Therapeutics, Spark Therapeutics, Voyager Therapeutics, NightstaRx

What are the Application segmentation covered in the Adeno-Associated Virus Vectors in Gene Therapy Market report?

Ans: The Applications covered in the Adeno-Associated Virus Vectors in Gene Therapy Market report are Alzheimer's Disease, Cystic Dibrosis, Hemophilia B, Parkinson's Disease

What are the Type segmentation covered in the Adeno-Associated Virus Vectors in Gene Therapy Market report?

Ans: The Types covered in the Adeno-Associated Virus Vectors in Gene Therapy Market report are Serotype 2 (AVV 2), Synthetic Serotypes, Others

1 Adeno-Associated Virus Vectors in Gene Therapy Market Overview

1.1 Product Overview and Scope of Adeno-Associated Virus Vectors in Gene Therapy

1.2 Adeno-Associated Virus Vectors in Gene Therapy Segment by Type

1.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2024-2030)

1.2.2 Serotype 2 (AVV 2)

1.2.3 Synthetic Serotypes

1.2.4 Others

1.3 Adeno-Associated Virus Vectors in Gene Therapy Segment by Application

1.3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Value by Application: (2024-2030)

1.3.2 Alzheimer's Disease

1.3.3 Cystic Dibrosis

1.3.4 Hemophilia B

1.3.5 Parkinson's Disease

1.4 Global Adeno-Associated Virus Vectors in Gene Therapy Market Size Estimates and Forecasts

1.4.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue 2019-2030

1.4.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales 2019-2030

1.4.3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Average Price (2019-2030)

1.5 Assumptions and Limitations

2 Adeno-Associated Virus Vectors in Gene Therapy Market Competition by Manufacturers

2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Manufacturers (2019-2024)

2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Manufacturers (2019-2024)

2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Average Price by Manufacturers (2019-2024)

2.4 Global Adeno-Associated Virus Vectors in Gene Therapy Industry Ranking 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Product Type & Application

2.7 Adeno-Associated Virus Vectors in Gene Therapy Market Competitive Situation and Trends

2.7.1 Adeno-Associated Virus Vectors in Gene Therapy Market Concentration Rate

2.7.2 The Global Top 5 and Top 10 Largest Adeno-Associated Virus Vectors in Gene Therapy Players Market Share by Revenue

2.7.3 Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3)

2.8 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Adeno-Associated Virus Vectors in Gene Therapy Retrospective Market Scenario by Region

3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region: 2019 Versus 2023 Versus 2030

3.2 Global Adeno-Associated Virus Vectors in Gene Therapy Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2019-2030

3.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2019-2024

3.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region: 2025-2030

3.3 Global Adeno-Associated Virus Vectors in Gene Therapy Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2019-2030

3.3.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2019-2024

3.3.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2025-2030

3.4 North America Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country

3.4.1 North America Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030

3.4.2 North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2030)

3.4.3 North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2030)

3.4.4 United States

3.4.5 Canada

3.5 Europe Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country

3.5.1 Europe Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030

3.5.2 Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2030)

3.5.3 Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2030)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country

3.6.1 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030

3.6.2 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2030)

3.6.3 Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2030)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country

3.7.1 Latin America Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030

3.7.2 Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2030)

3.7.3 Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2030)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Market Facts & Figures by Country

3.8.1 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Market Size by Country: 2019 VS 2023 VS 2030

3.8.2 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2030)

3.8.3 Middle East and Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2030)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2019-2030)

4.1.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2019-2024)

4.1.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Type (2025-2030)

4.1.3 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2019-2030)

4.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2019-2030)

4.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2019-2024)

4.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Type (2025-2030)

4.2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2019-2030)

4.3 Global Adeno-Associated Virus Vectors in Gene Therapy Price by Type (2019-2030)

5 Segment by Application

5.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2019-2030)

5.1.1 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2019-2024)

5.1.2 Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Application (2025-2030)

5.1.3 Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2019-2030)

5.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2019-2030)

5.2.1 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2019-2024)

5.2.2 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Application (2025-2030)

5.2.3 Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2019-2030)

5.3 Global Adeno-Associated Virus Vectors in Gene Therapy Price by Application (2019-2030)

6 Key Companies Profiled

6.1 Amicus Therapeutics

6.1.1 Amicus Therapeutics Corporation Information

6.1.2 Amicus Therapeutics Description and Business Overview

6.1.3 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.1.4 Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.1.5 Amicus Therapeutics Recent Developments/Updates

6.2 Asklepios Biopharmaceutical

6.2.1 Asklepios Biopharmaceutical Corporation Information

6.2.2 Asklepios Biopharmaceutical Description and Business Overview

6.2.3 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.2.4 Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.2.5 Asklepios Biopharmaceutical Recent Developments/Updates

6.3 BioMarin Pharmaceutical

6.3.1 BioMarin Pharmaceutical Corporation Information

6.3.2 BioMarin Pharmaceutical Description and Business Overview

6.3.3 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.3.4 BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.3.5 BioMarin Pharmaceutical Recent Developments/Updates

6.4 Coave Therapeutics

6.4.1 Coave Therapeutics Corporation Information

6.4.2 Coave Therapeutics Description and Business Overview

6.4.3 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.4.5 Coave Therapeutics Recent Developments/Updates

6.5 MeiraGTx

6.5.1 MeiraGTx Corporation Information

6.5.2 MeiraGTx Description and Business Overview

6.5.3 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.5.4 MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.5.5 MeiraGTx Recent Developments/Updates

6.6 Neurocrine Biosciences

6.6.1 Neurocrine Biosciences Corporation Information

6.6.2 Neurocrine Biosciences Description and Business Overview

6.6.3 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.6.4 Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.6.5 Neurocrine Biosciences Recent Developments/Updates

6.7 Pfizer

6.6.1 Pfizer Corporation Information

6.6.2 Pfizer Description and Business Overview

6.6.3 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.4.4 Pfizer Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.7.5 Pfizer Recent Developments/Updates

6.8 Roche Holding

6.8.1 Roche Holding Corporation Information

6.8.2 Roche Holding Description and Business Overview

6.8.3 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.8.4 Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.8.5 Roche Holding Recent Developments/Updates

6.9 Sangamo Therapeutics

6.9.1 Sangamo Therapeutics Corporation Information

6.9.2 Sangamo Therapeutics Description and Business Overview

6.9.3 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.9.4 Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.9.5 Sangamo Therapeutics Recent Developments/Updates

6.10 Sarepta Therapeutics

6.10.1 Sarepta Therapeutics Corporation Information

6.10.2 Sarepta Therapeutics Description and Business Overview

6.10.3 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.10.4 Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.10.5 Sarepta Therapeutics Recent Developments/Updates

6.11 Spark Therapeutics

6.11.1 Spark Therapeutics Corporation Information

6.11.2 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Description and Business Overview

6.11.3 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.11.4 Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.11.5 Spark Therapeutics Recent Developments/Updates

6.12 Voyager Therapeutics

6.12.1 Voyager Therapeutics Corporation Information

6.12.2 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Description and Business Overview

6.12.3 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.12.4 Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.12.5 Voyager Therapeutics Recent Developments/Updates

6.13 NightstaRx

6.13.1 NightstaRx Corporation Information

6.13.2 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Description and Business Overview

6.13.3 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Sales, Revenue and Gross Margin (2019-2024)

6.13.4 NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Product Portfolio

6.13.5 NightstaRx Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Adeno-Associated Virus Vectors in Gene Therapy Industry Chain Analysis

7.2 Adeno-Associated Virus Vectors in Gene Therapy Key Raw Materials

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Adeno-Associated Virus Vectors in Gene Therapy Production Mode & Process

7.4 Adeno-Associated Virus Vectors in Gene Therapy Sales and Marketing

7.4.1 Adeno-Associated Virus Vectors in Gene Therapy Sales Channels

7.4.2 Adeno-Associated Virus Vectors in Gene Therapy Distributors

7.5 Adeno-Associated Virus Vectors in Gene Therapy Customers

8 Adeno-Associated Virus Vectors in Gene Therapy Market Dynamics

8.1 Adeno-Associated Virus Vectors in Gene Therapy Industry Trends

8.2 Adeno-Associated Virus Vectors in Gene Therapy Market Drivers

8.3 Adeno-Associated Virus Vectors in Gene Therapy Market Challenges

8.4 Adeno-Associated Virus Vectors in Gene Therapy Market Restraints

9 Research Finding and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Amicus Therapeutics

Asklepios BioPharmaceutical

BioMarin Pharmaceutical

Coave Therapeutics

MeiraGTx Limited

Neurocrine Biosciences

List of Tables

Table 1. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2024-2030) & (US$ Million)

Table 2. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Application (2024-2030) & (US$ Million)

Table 3. Global Adeno-Associated Virus Vectors in Gene Therapy Market Competitive Situation by Manufacturers in 2023

Table 4. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) of Key Manufacturers (2019-2024)

Table 5. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Manufacturers (2019-2024)

Table 6. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Manufacturers (2019-2024)

Table 7. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Share by Manufacturers (2019-2024)

Table 8. Global Market Adeno-Associated Virus Vectors in Gene Therapy Average Price (US$/Kg) of Key Manufacturers (2019-2024)

Table 9. Global Key Players of Adeno-Associated Virus Vectors in Gene Therapy, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Product Type & Application

Table 12. Global Key Manufacturers of Adeno-Associated Virus Vectors in Gene Therapy, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Adeno-Associated Virus Vectors in Gene Therapy by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Adeno-Associated Virus Vectors in Gene Therapy as of 2023)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Table 17. Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2019-2024) & (Kg)

Table 18. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2019-2024)

Table 19. Global Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2025-2030) & (Kg)

Table 20. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2025-2030)

Table 21. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2019-2024) & (US$ Million)

Table 22. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2019-2024)

Table 23. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2025-2030) & (US$ Million)

Table 24. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2025-2030)

Table 25. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 26. North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2024) & (Kg)

Table 27. North America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2025-2030) & (Kg)

Table 28. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 29. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 30. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 31. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2024) & (Kg)

Table 32. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2025-2030) & (Kg)

Table 33. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 34. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 35. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 36. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2019-2024) & (Kg)

Table 37. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales by Region (2025-2030) & (Kg)

Table 38. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2019-2024) & (US$ Million)

Table 39. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue by Region (2025-2030) & (US$ Million)

Table 40. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 41. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2024) & (Kg)

Table 42. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2025-2030) & (Kg)

Table 43. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 44. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 45. Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 46. Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2019-2024) & (Kg)

Table 47. Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Sales by Country (2025-2030) & (Kg)

Table 48. Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2019-2024) & (US$ Million)

Table 49. Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue by Country (2025-2030) & (US$ Million)

Table 50. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Type (2019-2024)

Table 51. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Type (2025-2030)

Table 52. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2019-2024)

Table 53. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Type (2025-2030)

Table 54. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Type (2019-2024)

Table 55. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Type (2025-2030)

Table 56. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2019-2024)

Table 57. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Type (2025-2030)

Table 58. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2019-2024)

Table 59. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2025-2030)

Table 60. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Application (2019-2024)

Table 61. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg) by Application (2025-2030)

Table 62. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2019-2024)

Table 63. Global Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Application (2025-2030)

Table 64. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Application (2019-2024)

Table 65. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue (US$ Million) by Application (2025-2030)

Table 66. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2019-2024)

Table 67. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Application (2025-2030)

Table 68. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2019-2024)

Table 69. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2025-2030)

Table 70. Amicus Therapeutics Corporation Information

Table 71. Amicus Therapeutics Description and Business Overview

Table 72. Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 73. Amicus Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product

Table 74. Amicus Therapeutics Recent Developments/Updates

Table 75. Asklepios Biopharmaceutical Corporation Information

Table 76. Asklepios Biopharmaceutical Description and Business Overview

Table 77. Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 78. Asklepios Biopharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product

Table 79. Asklepios Biopharmaceutical Recent Developments/Updates

Table 80. BioMarin Pharmaceutical Corporation Information

Table 81. BioMarin Pharmaceutical Description and Business Overview

Table 82. BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 83. BioMarin Pharmaceutical Adeno-Associated Virus Vectors in Gene Therapy Product

Table 84. BioMarin Pharmaceutical Recent Developments/Updates

Table 85. Coave Therapeutics Corporation Information

Table 86. Coave Therapeutics Description and Business Overview

Table 87. Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 88. Coave Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product

Table 89. Coave Therapeutics Recent Developments/Updates

Table 90. MeiraGTx Corporation Information

Table 91. MeiraGTx Description and Business Overview

Table 92. MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 93. MeiraGTx Adeno-Associated Virus Vectors in Gene Therapy Product

Table 94. MeiraGTx Recent Developments/Updates

Table 95. Neurocrine Biosciences Corporation Information

Table 96. Neurocrine Biosciences Description and Business Overview

Table 97. Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 98. Neurocrine Biosciences Adeno-Associated Virus Vectors in Gene Therapy Product

Table 99. Neurocrine Biosciences Recent Developments/Updates

Table 100. Pfizer Corporation Information

Table 101. Pfizer Description and Business Overview

Table 102. Pfizer Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 103. Pfizer Adeno-Associated Virus Vectors in Gene Therapy Product

Table 104. Pfizer Recent Developments/Updates

Table 105. Roche Holding Corporation Information

Table 106. Roche Holding Description and Business Overview

Table 107. Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 108. Roche Holding Adeno-Associated Virus Vectors in Gene Therapy Product

Table 109. Roche Holding Recent Developments/Updates

Table 110. Sangamo Therapeutics Corporation Information

Table 111. Sangamo Therapeutics Description and Business Overview

Table 112. Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 113. Sangamo Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product

Table 114. Sangamo Therapeutics Recent Developments/Updates

Table 115. Sarepta Therapeutics Corporation Information

Table 116. Sarepta Therapeutics Description and Business Overview

Table 117. Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 118. Sarepta Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product

Table 119. Sarepta Therapeutics Recent Developments/Updates

Table 120. Spark Therapeutics Corporation Information

Table 121. Spark Therapeutics Description and Business Overview

Table 122. Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 123. Spark Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product

Table 124. Spark Therapeutics Recent Developments/Updates

Table 125. Voyager Therapeutics Corporation Information

Table 126. Voyager Therapeutics Description and Business Overview

Table 127. Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 128. Voyager Therapeutics Adeno-Associated Virus Vectors in Gene Therapy Product

Table 129. Voyager Therapeutics Recent Developments/Updates

Table 130. NightstaRx Corporation Information

Table 131. NightstaRx Description and Business Overview

Table 132. NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Sales (Kg), Revenue (US$ Million), Price (US$/Kg) and Gross Margin (2019-2024)

Table 133. NightstaRx Adeno-Associated Virus Vectors in Gene Therapy Product

Table 134. NightstaRx Recent Developments/Updates

Table 135. Key Raw Materials Lists

Table 136. Raw Materials Key Suppliers Lists

Table 137. Adeno-Associated Virus Vectors in Gene Therapy Distributors List

Table 138. Adeno-Associated Virus Vectors in Gene Therapy Customers List

Table 139. Adeno-Associated Virus Vectors in Gene Therapy Market Trends

Table 140. Adeno-Associated Virus Vectors in Gene Therapy Market Drivers

Table 141. Adeno-Associated Virus Vectors in Gene Therapy Market Challenges

Table 142. Adeno-Associated Virus Vectors in Gene Therapy Market Restraints

Table 143. Research Programs/Design for This Report

Table 144. Key Data Information from Secondary Sources

Table 145. Key Data Information from Primary Sources

List of Figures

Figure 1. Product Picture of Adeno-Associated Virus Vectors in Gene Therapy

Figure 2. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Type (2024-2030) & (US$ Million)

Figure 3. Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Type in 2023 & 2030

Figure 4. Serotype 2 (AVV 2) Product Picture

Figure 5. Synthetic Serotypes Product Picture

Figure 6. Others Product Picture

Figure 7. Global Adeno-Associated Virus Vectors in Gene Therapy Market Value Comparison by Application (2024-2030) & (US$ Million)

Figure 8. Global Adeno-Associated Virus Vectors in Gene Therapy Market Share by Application in 2023 & 2030

Figure 9. Alzheimer's Disease

Figure 10. Cystic Dibrosis

Figure 11. Hemophilia B

Figure 12. Parkinson's Disease

Figure 13. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 14. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size (2019-2030) & (US$ Million)

Figure 15. Global Adeno-Associated Virus Vectors in Gene Therapy Sales (2019-2030) & (Kg)

Figure 16. Global Adeno-Associated Virus Vectors in Gene Therapy Average Price (US$/Kg) & (2019-2030)

Figure 17. Adeno-Associated Virus Vectors in Gene Therapy Report Years Considered

Figure 18. Adeno-Associated Virus Vectors in Gene Therapy Sales Share by Manufacturers in 2023

Figure 19. Global Adeno-Associated Virus Vectors in Gene Therapy Revenue Share by Manufacturers in 2023

Figure 20. The Global 5 and 10 Largest Adeno-Associated Virus Vectors in Gene Therapy Players: Market Share by Revenue in 2023

Figure 21. Adeno-Associated Virus Vectors in Gene Therapy Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2019 VS 2023

Figure 22. Global Adeno-Associated Virus Vectors in Gene Therapy Market Size by Region (US$ Million): 2019 VS 2023 VS 2030

Figure 23. North America Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2019-2030)

Figure 24. North America Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2019-2030)

Figure 25. United States Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 26. Canada Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 27. Europe Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2019-2030)

Figure 28. Europe Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2019-2030)

Figure 29. Germany Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 30. France Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 31. U.K. Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 32. Italy Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 33. Russia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 34. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Region (2019-2030)

Figure 35. Asia Pacific Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Region (2019-2030)

Figure 36. China Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 37. Japan Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 38. South Korea Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 39. India Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 40. Australia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 41. China Taiwan Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 42. Indonesia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 43. Thailand Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 44. Malaysia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 45. Latin America Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2019-2030)

Figure 46. Latin America Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2019-2030)

Figure 47. Mexico Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 48. Brazil Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 49. Argentina Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 50. Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Sales Market Share by Country (2019-2030)

Figure 51. Middle East & Africa Adeno-Associated Virus Vectors in Gene Therapy Revenue Market Share by Country (2019-2030)

Figure 52. Turkey Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 53. Saudi Arabia Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 54. UAE Adeno-Associated Virus Vectors in Gene Therapy Revenue Growth Rate (2019-2030) & (US$ Million)

Figure 55. Global Sales Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Type (2019-2030)

Figure 56. Global Revenue Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Type (2019-2030)

Figure 57. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Type (2019-2030)

Figure 58. Global Sales Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Application (2019-2030)

Figure 59. Global Revenue Market Share of Adeno-Associated Virus Vectors in Gene Therapy by Application (2019-2030)

Figure 60. Global Adeno-Associated Virus Vectors in Gene Therapy Price (US$/Kg) by Application (2019-2030)

Figure 61. Adeno-Associated Virus Vectors in Gene Therapy Value Chain

Figure 62. Adeno-Associated Virus Vectors in Gene Therapy Production Process

Figure 63. Channels of Distribution (Direct Vs Distribution)

Figure 64. Distributors Profiles

Figure 65. Bottom-up and Top-down Approaches for This Report

Figure 66. Data Triangulation

Figure 67. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

RELATED REPORTS

Global Self-destructing Vaccine Syringes Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-34F14139

Mon Aug 26 00:00:00 UTC 2024

Add to Cart

Global Adeno-Associated Virus Vectors in Gene Therapy Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-34W12809

Mon Aug 26 00:00:00 UTC 2024

Add to Cart

Global Sterile Self-Disable Vaccine Syringes Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-24A14215

Mon Aug 26 00:00:00 UTC 2024

Add to Cart

Global Legionella Routine Testing Market Research Report 2024

120 Pages

Type: Report

Code: QYRE-Auto-22D11845

Sun Aug 25 00:00:00 UTC 2024

Add to Cart

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions